Exbio — Research products — Antibodies — Serum, plasma, and secreted proteins — Anti-Hu C3b/iC3b Alexa Fluor<sup>®</sup> 647

Anti-Hu C3b/iC3b Alexa Fluor^® 647

Regulatory status

RUO

Antigen

C3b/iC3b

Clone

3E7

Format

Alexa Fluor^® 647

Reactivity

Human, Non-human primates

Application

FC (QC tested)

Excitation laser

red (633 nm)

Variant

100 tests

A6-950-T100

In stock

248.60 USD

Variant

100 tests

A6-950-T100

In stock

248.60 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody 3E7 recognizes complement component C3b and iC3b. It does not cross-react with C3d.

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Reactivity

Human, Non-human primates

Immunogen

human complement component C3b

Preparation

Purified antibody is conjugated with Alexa Fluor^® 647 NHS ester under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Alexa Fluor^®, Pacific Blue™ and Pacific Orange™ are registered trademarks of Life Technologies Corporation.

This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.

Other names

complement component C3, complement component C3b, complement component iC3b

Antigen description

Complement component C3 plays a key role in the activation of complement system. In classical complement system pathway the activated C2 and C4 form classical C3-convertase (C4b2b) which cleaves C3 into C3a and C3b. In alternative complement system pathway C3 is cleaved by alternative C3-convertase (C3bBb), composed of C3b (which can be generated also by spontaneous hydrolysis of C3) and the activated form of factor B. C3b activates downstream cascade leading to formation of pores in the plasma membrane of attacked cell. C3b and its proteolytically inactive form iC3b also serve as important opsonins. C3b can generate C3f, as well as the iC3b can be further cleaved into C3c, C3d and C3g. Complement system is regulated by effective inactivation of free C3b by factor H and factor I. C3b attached to the surface of its target is protected from this inactivation. Complement system is also regulated by other proteins, e.g. CD35, CD46, CD55, or CD59. Undesired activation of complement cascade can lead to severe diseases such as PNH, rheumatoid arthritis, macular degeneration and other. Recently it has been demonstrated to take part in complications associated with Covid-19.

Entrez Gene ID 718

UniProt ID P01024

Flow cytometry surface staining pattern of PHA stimulated human peripheral whole blood stained using anti-human C3b/iC3b (3E7) Alexa Fluor® 647 antibody (concentration in sample 0.19 μg/ml).

Flow cytometry multicolor surface staining pattern of human lymphocytes stained using anti-human CD3 (UCHT1) PE antibody (20 μl reagent / 100 μl of peripheral whole blood) and anti-human C3b/iC3b (3E7) Alexa Fluor® 647 antibody (concentration in sample 0.19 μg/ml).

Separation of human CD3 positive C3b/iC3b positive T cells (red-filled) from CD3 negative C3b/iC3b negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human PHA stimulated peripheral whole blood stained using anti-human C3b/iC3b (3E7) Alexa Fluor® 647 antibody (concentration in sample 0.19 μg/ml).

Product specific references:

Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP: Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol. 2007 Sep 15;179(6):4263-71.
PubMed

Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP: An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. 2003 Feb 1;101(3):1071-9.
PubMed

Pokrass MJ, Liu MF, Lindorfer MA, Taylor RP: Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy. Mol Immunol. 2013 Dec;56(4):549-60.
PubMed

DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP: Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol Immunol. 2006 Mar;43(7):1010-9.
PubMed

Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ: A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 2010 Mar 18;115(11):2283-91.
PubMed